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Available online 20 July 2019 Introduction: Accurate early diagnosis of Parkinson's disease is hampered by its long prodromal period and the variable
manifestations of its motor symptoms. While olfactory dysfunction can occur before motor-symptom onset and serve
as a non-disease-specific diagnostic aid, its underlying causes are incompletely understood.
Methods: Correlation analyses, univariate density estimates, ANOVA and regression evaluated relationships between
scores on the Montreal Cognitive Assessment and Hopkins Verbal Learning Test and those on the University of Penn-
sylvania Smell Identification Test in 1280 Parkinson's Progression Markers Initiative subjects placed into five diagnos-
tic categories. Structural equation modeling identified cognitive measures having significant indirect effects on
olfactory-function-test scores.
Results: Global cognition, verbal learning and memory, attention, delayed-recall, and visuospatial/executive function
scores show weak-to-moderate, significant associations with olfactory-function-test scores. Associations are stronger in
symptomatic than asymptomatic subjects having mutations in LRRK2, GBA or SNCA. Score distributions are nonuniform
across diagnostic categories. Linear regression found that all cognitive measures except attention predicted olfactory-
function-test scores. Three structural equation models assessing indirect effects of verbal learning/memory with either
global cognition, visuospatial/executive function, or delayed-recall had a good statisticalfit to the data. Only verbal learn-
ing/memory scores significantly help explain olfactory-function-test scores in all symptomatic diagnostic categories
(−0.56 < b<−0.23, 0.001 < P< .005). Visuospatial/executive-function test scores help explain olfactory-function-
test scores in both genetic Parkinson's disease diagnostic categories (−0.25 < b<−0.17, 0.032 < P< .033).
Conclusion: Impaired verbal learning/memory and visuospatial/executive function contributes to lower performance on
olfactory function tests in Parkinson's disease. As both of these domains impact decision-making, decision-making in
turn may impact olfactory assessment in Parkinson's disease.
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1. Introduction
Accurate diagnosis of Parkinson's disease (PD) is complicated by the var-
iable manifestations of motor and non-motor symptoms. Assessment of olfac-
tory dysfunction, an early non-motor symptom present in up to 90% of PD
patients [1], may serve as an ancillary diagnostic criterion [2–5]. However,
it is not specific to PD: it is found in other neurodegenerative diseases and
healthy aging [6,7]. It is therefore important to understand how its onset
and progression relates to PD motor and non-motor manifestations.
Interpreting olfactory stimuli requires primary sensory detection along
with multiple levels of associative sensory-signal processing. Clinically
used tests of olfactory function implicitly measure multiple domains, as
tests of odor detection, discrimination, and identification require informa-
tion processing within the olfactory bulb and higher-order associative cen-
ters. They may be sensitive to specific types of cognitive impairment, such
as memory decline that affects odor-memory retention or the associative
processing of an odor memory.
If a subtle cognitive deficit contributes to lower scores on olfactory func-
tion tests, then subjects retaining some olfactory function might obtain simi-
lar scores but misidentify different odors upon retesting. Such odor-
identification irreproducibility was observed but could not be explained by
global-cognition test scores [8]. This suggests that routinely used clinical
measures of cognitive performance in PD may have limited sensitivity to de-
tect the cognitive deficits that impact performance on olfactory-function tests.
Here, we identify specific cognitive deficits that help explain lower
scores on tests of olfactory function in PD and quantify the magnitude of
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their indirect effects by developing structural equation models (SEM) using
data from the Parkinson's Progression Marker Initiative (PPMI). This report
extends previous research demonstrating that memory is strongly related to
olfaction [9–11] and builds on previously established correlative associa-
tions and predictive relationships between deficits in olfaction and verbal
learning/memory in PD [12,13]. In addition to quantifying the contribu-
tions of verbal learning/memory, we also assess visuospatial/executive
function, which is frequently impaired in PD [14], attention, and delayed-
recall. Quantifying how poorer performance on tests of these cognitive
measures contributes to lower scores on olfactory function tests provides in-
sight into how and why olfactory test scores decline in some PD patients,
and how potentially subtle alterations in cognition in PD impact seemingly
unrelated clinical assessments.
2. Subjects and methods
2.1. Assessments
Data used in the preparation of this article were obtained from the PPMI
database (www.ppmi-info.org/data) in September 2018. For study infor-
mation, visit www.ppmi-info.org. We analyzed scores on the University of
Pennsylvania Smell Identification Test (UPSIT), a forced-choice test of
odor identification [15], the Hopkins Verbal Learning Test (HVLT), an as-
sessment of verbal learning andmemory that is a significant predictor of de-
mentia [16,17], and the Montreal Cognitive Assessment (MoCA), which
evaluates visuospatial/executive function, attention/concentration, nam-
ing, language, immediate and delayed-recall, calculations and orientation,
and accurately assesses cognitive impairment in PD [14,18]. We used
only the three free-recall memory trials of the HVLT, since they and the
UPSIT similarly rely on the processes of short-term/working memory, se-
mantic and/or episodic memory, and association. They may be used in
the UPSIT to retain an odormemory while selecting amongwords for an ol-
factory cue, while they are used in the free-recall trials of the HVLT to recall
auditory cues (words read aloud). We also assessed MoCA subscores for vi-
suospatial/executive function (Visu-Exec), attention/concentration (Atten-
tion), and delayed-recall (Delayed-Recall), as these cognitive domains are
commonly and potentially differentially affected in PD and are also used
in olfactory coding and memory [19–21]. These subscores have utility in
understanding cognitive phenotypes of PD [14], akin to using Unified
Parkinson's Disease Rating Scale subscores in assessing motor subtypes.
Since the UPSIT, HVLT, and MoCA were administered together only at
study baseline, we analyzed only baseline assessments.
2.2. Subjects
We analyzed data from five well-defined PPMI-assigned diagnostic cat-
egories (https://www.ppmi-info.org/study-design/). The main diagnostic
categories were sporadic PD (≥2 of resting tremor, bradykinesia, or rigid-
ity, with resting tremor or bradykinesia required, or either asymmetric rest-
ing tremor or asymmetric bradykinesia; PD diagnosis≤2 years; Hoehn and
Yahr (H&Y) I-II; scan-confirmed dopaminergic deficit; ≥30 years at diag-
nosis; no dopaminergic medications≥6 months after baseline assessment)
and healthy controls (≥30 years, no active neurological disorder or first-
degree relative with idiopathic PD, MoCA≥26, scan-negative for dopami-
nergic deficit).We included two diagnostic categories of subjectswho are at
increased genetic-risk of developing PD, symptomatic-genetic-PD (motor
symptoms in sporadic-PD diagnostic category, PD diagnosis ≤7 years,
H&Y I-III, ≥18 years, and a LRRK2, GBA, or SNCA mutation) and
asymptomatic-genetic-PD (no PD diagnosis at baseline, ≥45 years, muta-
tion or first-degree relative with mutation in either LRRK2 or GBA, or
≥ 30 years, mutation or first-degree relative with mutation in SNCA), as
the disease phenotypes are similar to sporadic PD and their inclusion allows
for comparisons in individuals having a known disease cause before and
after motor-symptom onset. We included the possible-prodromal-PD diag-
nostic category (≥60 years, hyposmia and/or REM-behavior sleep disorder
(RBD)), as this is a potentially informative comparison group due to a high
prevalence of hyposmia (71% have UPSIT < 21).
2.3. ANOVA and SEM
Since MoCA, Visu-Exec, and UPSIT scores were somewhat skewed, we
used the robust maximum likelihood parameter estimator [22]. ANOVA
testing for homogeneity of variance revealed some violation (1.3:1 male:fe-
male). ANOVA t and F statistics are sufficiently robust to handle this viola-
tion [23].
We used SEM (Mplus version 7.11), which incorporates both factor and
regression analyses [24,25], to evaluate models in which cognitive pro-
cesses are hypothesized to have indirect effects on (i.e., help explain) the re-
lationship between olfactory dysfunction and a PPMI-diagnostic category,
relative to healthy controls. Significant models with a good fit to the data
had model chi-square (χ2) α ≥ 0.05, comparative fit index (CFI) ≥ 0.93
(1 = perfect fit), root mean square error of approximation (RMSEA)
≤0.08, and standard root mean square residual (SRMR) ≤0.08 [24]. We
used such models to infer whether a cognitive measure has an indirect ef-
fect on, or a significant role in explaining, the relationship between UPSIT
scores and a diagnostic category, and to infer its magnitude.
3. Results
3.1. Descriptive statistics and correlations
Table 1 presents descriptive statistics for study subjects and Pearson
zero-order correlations between study variables. The latter reveal weak-
to-moderate, significant positive associations between scores on tests of ol-
faction and cognition: if a subject had lower scores on one test, they tended
to score lower on the others as well. In contrast, scores showed weak nega-
tive correlations with age. To understand whether positive correlations be-
tween scores reflect similar score distributions in all diagnostic categories,
we compared their distributions and univariate density estimates [26] be-
tween diagnostic categories. Score distributions are nonuniform between
diagnostic categories (Fig. 1, Supplemental Figs. 1–2). Specifically, the dis-
tributions of UPSIT, HVLT, and MoCA scores in healthy controls are clearly
distinct from those in other diagnostic categories. Therefore, we asked how
the study measures were correlated for each of the diagnostic categories
compared to healthy controls (Supplemental Table 1). This confirmed pre-
viously demonstrated positive associations found in idiopathic PD between
scores on the USPIT and tests of verbal learning/memory [12,13], and dis-
covered significant associations between scores on the UPSIT, MoCA,
HVLT, Visu-Exec and Delayed-Recall in each symptomatic diagnostic cate-
gory. Strikingly, these associations are stronger in symptomatic than
asymptomatic subjectswith genetic-PD. Taken together, these analyses sug-
gest that the underlying neurodegenerative process(es) affect
(s) interactions between the tested cognitive domains.
3.2. ANOVA
Separate, univariate ANOVAs investigatedwhethermeanUPSIT, HVLT,
MoCA, Visu-Exec, Delayed-Recall and Attention scores differ between the
five diagnostic categories, holding age and sex constant as covariates.
There are significant differences between the effects of diagnostic catego-
ries on scores on the UPSIT (F6,1273 = 138.63, P = 3.19 × 10−135, η2 =
0.395), HVLT (F6,1273 = 31.68, P = 1.20 × 10−35, η2 = 0.126), and
MoCA (F6,1269 = 26.23, P = 1.56 × 10−29, η2 = 0.011), and on MoCA
subscores for Visu-Exec (F6,1273 = 9.78, P = 1.47 × 10−10, η2 = 0.044),
Delayed-Recall (F6,1273 = 23.21, P = 5.54 × 10−13, η2 = 0.049) and At-
tention (F6,1273 = 9.245, P = 6.18 × 10−10, η2 = 0.037).
Bonferroni post-hoc analyses evaluated significant differences in mean
scores between pairs of diagnostic categories (Table 2). Healthy controls
had higher means on all tests than subjects in symptomatic diagnostic cat-
egories, and higher means on all tests except the HVLT than
asymptomatic-genetic-PD subjects. In turn, asymptomatic-genetic-PD
A.T. Mertens et al. Clinical Parkinsonism & Related Disorders 1 (2019) xxx
2
subjects had means higher than those in all symptomatic diagnostic catego-
ries, except for having lower Delayed-Recall means than sporadic-PD sub-
jects. Symptomatic-genetic-PD subjects, compared to sporadic-PD
subjects, had lower UPSIT, MoCA and Attention means, higher VisuExec
means, and similar HVLT and Delayed-Recall means. Possible-prodromal-
PD subjects had means similar to or lower than those in all other diagnostic
categories, except for having higher Visu-Execmeans than sporadic-PD sub-
jects. PPMI-inclusion criteria may contribute to differences between some
diagnostic categories: inclusion criteria for healthy controls specified
MoCA≥26 and they had greaterMoCAmeans than all other diagnostic cat-
egories; symptomatic-genetic-PD subjects with disease duration ≤7 years
had lower UPSIT, MoCA, and Attention means than sporadic-PD subjects
with disease duration ≤2 years; possible-prodromal-PD subjects had RBD
and/or hyposmia.
3.3. The indirect effects of cognitive processes
Before building SEM models to evaluate the indirect effects of cognitive
processes, we confirmed that PPMI diagnostic categories are predictive of
UPSIT scores by regressing UPSIT scores on the PPMI diagnostic categories.
Mirroring the ANOVA results, UPSIT scores in the sporadic-PD,
asymptomatic-genetic-PD, symptomatic-genetic-PD and possible-prodromal-
PD diagnostic categories were significantly different from those in the
healthy-control category. Specifically, healthy controls hadUPSIT scores clos-
est to asymptomatic-genetic-PD (b=−1.05, Standard Error (SE)=0.44, z=
−2.38, P= .017) while symptomatic individuals showed larger differences
[symptomatic-genetic-PD (b = −12.56, SE = 0.69, z = −18.21, P <
.001), sporadic-PD (b = −10.62, SE = 0.52, z = −20.44, P < .001) and
possible-prodromal-PD (b=−16.84, SE= 0.90, z=−18.69, P< .001)].
Thus, subjects in all symptomatic diagnostic categories had poorer olfactory
function than healthy controls. Overall, the five diagnostic categories ex-
plained 36.6% of the variance in UPSIT scores.
We also used regression analysis to verify that the potentially mediating
variables (MoCA and HVLT) are predictive of UPSIT scores after controlling
for associations between HVLT and MoCA scores. MoCA scores (b = 0.07,
SE= 0.03, z = 2.31, P = .021) and HVLT scores (b = 0.25, SE = 0.03, z
= 8.46, P < .001) significantly predicted UPSIT scores and together ex-
plained 8.3% of the variance in UPSIT scores. In separate, simple
Fig. 1. Graphical comparison of univariate density estimates for study variables. (A) UPSIT score. (B) HVLT score. (C) MoCA score. (D) Visuospatial/Executive Subscore.
(E) Delayed-Recall Subscore. (F) Attention Subscore. Table cells within each panel are shaded to indicate the P value (white: P ≥ .05, gray: 0.05 > P ≥ .001, black: P <
.001) obtained from pairwise nonparametric bootstrap tests of equal densities using 1000 permutations [26]. PPMI-defined diagnostic categories: HC = healthy controls;
GENUN = individuals with asymptomatic genetic (LRRK2, SNCA, or GBA) PD; GENPD = individuals with symptomatic genetic PD; SPD = individuals with sporadic PD
at baseline; PROD (possible prodromal PD) = individuals diagnosed with hyposmia and/or RBD.
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regressions of UPSIT onMoCA and UPSIT on HVLT, theMoCAwas a signif-
icant predictor of the UPSIT (b=0.18, SE=0.03, z=6.54, P< .001), as
was the HVLT (b = 0.28, SE = 0.03, z = 10.88, P < .001). Though each
individually was a significant predictor of the UPSIT, when both were con-
sidered as joint predictors, the MoCA lost more of its predictive magnitude
and strength than did the HVLT.
Since the diagnostic categories, HVLT scores, andMoCA scores were all
predictive of UPSIT scores, we built an SEMmodel to assess whether HVLT
andMoCA scores have indirect effects on the relationship between the diag-
nostic categories and UPSIT scores. This model compared each of the PD-
related diagnostic categories to healthy controls, included UPSIT scores
regressed onto all diagnostic categories, the indirect effects of HVLT and
MoCA scores on these relationships, and the effects of the age and sex as co-
variates, since olfactory function declines during healthy aging and differs
between sexes. The relationship between HVLT scores and the
asymptomatic-genetic-PD diagnostic category was not significant, so this
association was set to zero to give the model one degree of freedom. That
had no effect on other model relationships. The resulting model (Fig. 2A)
was a good fit to the data (χ2(1) = 0.95, P = .329, CFI = 1.00, RMSEA
= 0.00, SRMR = 0.004) and explained 40.7% of the variability in
UPSIT, 12.9% in HVLT and 10.7% in MoCA scores. Thus, 40.7% of the var-
iability in UPSIT scores is attributable to age, sex, diagnostic category,
HVLT scores and MoCA scores.
In this model, MoCA scores do not have significant indirect effects on
the relationships between each of the four non-healthy-control diagnostic
categories and UPSIT scores. In contrast, HVLT scores have significant indi-
rect effects on the relationships between all symptomatic diagnostic catego-
ries and UPSIT scores. Importantly, this model indicates that HVLT scores
provide a better explanation for UPSIT scores in symptomatic diagnostic
categories than do MoCA scores.
Given our and others' [27,28] results documenting the relationship be-
tween MoCA scores and olfactory function, we assessed the magnitude of
the indirect effects of MoCA scores without HVLT scores. UPSIT scores
were regressed against the asymptomatic-genetic-PD, symptomatic-genetic-
PD, sporadic-PD and possible-prodromal-PD diagnostic categories, compar-
ing them to healthy controls with age and sex as covariates, and using
MoCA scores as amediating variable. The resulting regressionmodel was sig-
nificant (F7,1268 = 120.6, P=1×10−135, R2= 0.4) and explained 40% of
the variability in UPSIT scores and 11% of the variability in MoCA scores.
Age, sex, the non-healthy-control diagnostic categories, and MoCA scores
were significant predictors of UPSIT scores (Supplemental Table 2). MoCA
scores have significant indirect effects on the relationship between UPSIT
scores and the diagnostic categories of asymptomatic-genetic-PD (b =
−0.45, P = .010), symptomatic-genetic-PD (b = −0.63, P = .012),
sporadic-PD (b = −0.27, P = .012), and possible-prodromal-PD (b =
−0.42, P = .013). Thus, MoCA scores do have significant indirect effects,
but they are no longer significant when HVLT scores also are included in
the model. Therefore, the HVLT more effectively captures the indirect effects
of cognition on the relationship between a diagnostic category and UPSIT
than does the MoCA.
To determine whether MoCA subscores for Visu-Exec, Attention or
Delayed-Recall, by themselves, have significant indirect effects, we re-
placed total MoCA scores with these subscores and tested them using re-
gression analyses. Only the Visu-Exec and Delayed-Recall subscores were
significant predictors of UPSIT scores. We then built SEM models to evalu-
ate the indirect effects of (1) Visu-Exec, (2) Delayed-Recall (3) Visu-Exec
and HVLT and (4) Delayed-Recall and HVLT.
Visu-Exec had significant indirect effects on the relationship between
UPSIT and the diagnostic categories of asymptomatic-genetic-PD (b =
−0.22, P = .008), symptomatic-genetic-PD (b = −0.32, P = .007),
sporadic-PD (b = −0.12, P = .030), and possible-prodromal-PD (b =
−0.45, P = .017). An SEM model with Visu-Exec and HVLT scores had a
good fit to the data (χ2(1) = 0.95, P = .329, CFI = 1.00, RMSEA= 0.00,
SRMR = 0.002) and explained 40.9% of the variability in UPSIT scores,
12.9% of the variability in HVLT scores and 4.3% of the variability in
Visu-Exec subscores (Fig. 2B). It revealed 1) significant indirect associations
Table 1
Descriptive statistics of study subjects and correlations between study variables.
Study variable Mean ± standard deviation Pearson correlation coefficient and P-valueb
PPMI diagnostic category Study variable
Healthy
controls
n = 198
F = 71
Asymptomatic
genetic Parkinson's
disease
n = 310
F = 187
Symptomatic
genetic Parkinson's
disease
n = 220
F = 113
Sporadic
Parkinson's
disease
n = 491
F = 169
Possible prodromal
Parkinson's disease
n = 61
F = 13
UPSIT
n =
1280
HVLT
n =
1280
MoCA
n =
1276
Visu-Exec
n =
1280
Delayed
recall
n =
1279
Attention
n =
1280
Age
n =
1280
UPSIT (40)a 34.0 ±
4.8
33.0 ± 4.9 21.5 ± 8.9 23.4 ± 8.7 17.2 ± 6.6 –
HVLT (30)a 26.0 ±
4.5
26.5 ± 5.2 24.0 ± 5.6 24.4 ± 4.9 22.0 ± 5.3 0.281
1.2 ×
10−24
–
MoCA (30)a 28.2 ±
1.1
26.7 ± 2.3 25.9 ± 3.5 27.1 ± 2.3 26.2 ± 3.6 0.182
6.2 ×
10−11
0.449
1.9 ×
10−64
–
Visu-Exec (5)a 4.66 ±
0.59
4.35 ± 0.88 4.22 ± 0.99 4.49 ± 0.80 4.03 ± 1.21 0.132
2.2 ×
10−6
0.195
1.9 ×
10−12
0.353
7.8 ×
10−39
–
Delayed-Recall
(5)a
3.88 ±
0.98
3.04 ± 1.57 3.22 ± 1.48 3.35 ± 1.41 3.31 ± 1.43 0.088
1.6 ×
10−3
0.243
1.1 ×
10−18
0.468
2.5 ×
10−70
0.185
2.8 ×
10−11
–
Attention (6)a 5.89 ±
0.32
5.72 ± 0.56 5.49 ± 0.90 5.76 ± 0.59 5.39 ± 1.37 0.104
2.1 ×
10−4
0.171
7.5 ×
10−10
0.395
5.5 ×
10−49
0.323
2.0 ×
10−32
0.227
2.1 ×
10−16
–
Age 67.4 ±
11.0
63.9 ± 7.4 64.4 ± 10.2 67.8 ± 9.8 72.8 ± 6.1 −0.190
7.4 ×
10−12
−0.258
6.4 ×
10−21
−0.160
8.3 ×
10−9
−0.090
1.3 ×
10−3
−0.088
1.6 ×
10−3
0.011
6.9 ×
10−1
–
a Maximum score or subscore on assessment.
b Correlations calculated with missing-value cases excluded pairwise, bold indicates significance at the 0.01 level (two-tailed). UPSIT: University of Pennsylvania Smell
Identification Test. HVLT: Hopkins Verbal Learning Test. MoCA: Montreal Cognitive Assessment Test. Visu-Exec: MoCA subscore for visuospatial and executive function. De-
layed-Recall: MoCA subscore for delayed recall. PPMI-defined diagnostic groups: Asymptomatic-genetic-Parkinson's-disease subjects have a mutation, or are a first-degree
relative of an individual having a mutation, in LRRK2, SNCA, or GBA; Symptomatic-genetic-Parkinson's-disease subjects have a mutation in LRRK2, SNCA, or GBA; Possi-
ble-prodromal-Parkinson's-disease subjects have REM-behavior sleep disorder and/or hyposmia.
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Table 2
ANOVA Bonferroni post-hoc analysis.
Healthy
controls
Asymptomatic genetic
Parkinson's disease
Symptomatic genetic
Parkinson's disease
Sporadic Parkinson's
disease
Possible prodromal
Parkinson's disease
A. UPSIT
Healthy controls –
Asymptomatic genetic Parkinson's disease −1.06 ± 0.67
0.82 to −2.94
1.000
–
Symptomatic genetic Parkinson's disease −12.56* ± 0.72
−14.58 to
−10.53
<0.001
−11.50* ± 0.65
−13.32 to −9.68
<0.001
–
Sporadic Parkinson's disease −10.56* ± 0.62
−12.36 to−8.89
<0.001
−9.57* ± 0.53
−11.07 to −8.07
<0.001
1.93* ± 0.60
0.26 to 3.61
0.012
–
Prodromal −16.84* ± 1.08
−19.85 to
−13.81
<0.001
−15.78* ± 1.03
−18.67 to −12.89
<0.001
−4.28* ± 1.06
−7.27 to −1.29
0.001
−6.21* ± 1.00
−9.01 to −3.41
<0.001
–
B. HVLT
Healthy controls –
Asymptomatic genetic Parkinson's disease 0.43 ± 0.46
−0.86 to 1.73
1.000
–
Symptomatic genetic Parkinson's disease −1.99* ± 0.50
−3.38 to −0.60
0.001
−2.43* ± 0.45
−3.68 to −1.17
<0.001
–
Sporadic Parkinson's disease −1.59* ± 0.43
−2.78 to −0.39
0.002
−2.02* ± 0.37
−3.05 to −0.99
<0.001
0.41 ± 0.41
−0.75 to 1.56
1.000
–
Prodromal −4.012* ± 0.74
−6.10 to −1.93
<0.001
−4.45* ± 0.71
−6.44 to −2.46
<0.001
−2.02 ± 0.73
−4.08 to 0.03
0.058
−2.43* ± 0.69
−4.36 to −0.50
0.004
–
C. MoCA.
Healthy controls –
Asymptomatic genetic Parkinson's disease −1.53* ± 0.23
−2.17 to −0.88
<0.001
–
Symptomatic genetic Parkinson's disease −2.28* ± 0.25
−2.97 to −1.59
<0.001
−0.75* ± 0.22
−1.38 to −0.13
0.007
–
Sporadic Parkinson's disease −1.10* ± 0.21
−1.69 to −0.50
<0.001
0.43 ± 0.18
−0.08 to 0.94
0.187
1.18* ± 0.20
0.61 to 1.76
<0.001
–
Prodromal −2.01* ± 0.37
−3.04 to −0.98
<0.001
−0.48 ± 0.35
−1.47 to 0.51
1.000
0.27 ± 0.36
−0.75 to 1.29
1.000
−0.91 ± 0.34
−1.87 to 0.05
0.076
–
D. MoCA subscore for visuospatial executive function
Healthy controls –
Asymptomatic genetic Parkinson's disease −0.30* ± 0.08
−0.52 to −0.08
0.001
–
Symptomatic genetic Parkinson's disease −0.43* ± 0.83
−0.67 to −0.20
<0.001
0.13 ± 0.08
−0.08 to 0.34
0.783
–
Sporadic Parkinson's disease −0.17 ± 0.07
−0.37 to 0.03
0.193
−0.13 ± 0.06
−0.31 to 0.04
0.301
−0.27* ± 0.07
−0.46 to −0.07
0.001
–
Prodromal −0.62* ± 0.13
−0.97 to −0.27
<0.001
0.32 ± 0.12
−0.01 to 0.66
0.070
0.19 ± 0.12
−0.16 to 0.54
1.000
0.46* ± 0.12
0.13 to 0.78
<0.001
–
E. MoCA subscore for delayed recall
Healthy controls –
Asymptomatic genetic Parkinson's disease −0.85* ± 0.13
−1.21 to −0.48
<0.001
–
Symptomatic genetic Parkinson's disease −0.66* ± 0.14
−1.05 to −0.27
<0.001
0.18 ± 0.13
−0.17 to 0.53
1.000
–
Sporadic Parkinson's disease −0.53* ± 0.12
−0.87 to −0.20
<0.001
0.31* ± 0.10
0.03 to 0.60
0.023
0.13 ± 0.12
−0.19 to 0.45
1.000
–
(continued on next page)
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of the HVLT on the relationships between the UPSIT and the three symp-
tomatic diagnostic categories and 2) significant indirect effects of the
Visu-Exec on the relationships between the UPSIT and the genetic diagnos-
tic categories, with the other symptomatic diagnostic categories ap-
proaching significance. As found for the SEM model including the HVLT
and MoCA, the HVLT also had stronger indirect effects on the
symptomatic-genetic-PD diagnostic category than the Visu-Exec. Strikingly,
Visu-Exec subscores provide a better explanation for UPSIT scores in the ge-
netic diagnostic categories than do total MoCA scores.
Delayed-Recall subscores have significant indirect effects on the rela-
tionship between UPSIT scores and the diagnostic categories of
asymptomatic-genetic-PD (b = −0.53, P = .017), symptomatic-genetic-
PD (b = −0.35, P = .019), and sporadic-PD (b = −0.24, P = .026), but
not possible-prodromal-PD (b = −0.01, P = .995). When incorporated
into a SEM model that also includes HVLT scores, however, the indirect ef-
fects of Delayed-Recall subscores lose significance, just as we found for total
MoCA scores when they were included in a model with HVLT scores
(Fig. 2C).
4. Discussion
In PD, olfactory dysfunction is a common early manifestation [2–6] and
cognitive dysfunction, specifically visuospatial and executive dysfunction,
is also common [29,30]. Analysis of PPMI data shows that scores on tests
of verbal learning/memory, global cognition, visuospatial-executive func-
tion, and delayed-recall are significant predictors of olfactory-function-
test scores. Furthermore, SEM analysis demonstrates that in the symptom-
atic PPMI diagnostic categories, verbal learning/memory is a better indirect
predictor of olfactory deficits than is global cognition. Furthermore,
visuospatial and executive function also has significant indirect effects.
We infer that the HVLT and Visu-Exec each assess cognitive processes
that are also utilized by the UPSIT, and that impairment in those processes
contribute to lowered olfactory-function-test scores in PD.
Both the UPSIT and HVLT are structured to utilize memory and/or
memory retrieval. The UPSIT requires working and/or short-term memory
processes to retain an odor memory while connecting it to semantic and/or
episodic long-term memory to establish an association with its name. The
HVLT presents auditory cues that must be retained in short-term memory
so they can be repeated back. Efficient recall can be aided by making con-
nections among the words using long-term memory. Scores on both tests
will be influenced by working and/or short-term memory capacity/pro-
cesses or memory retrieval. The significant indirect effects of HVLT scores
for UPSIT scores on the symptomatic diagnostic categories may arise be-
cause the HVLT is a good measure for the use of these cognitive domains
within the UPSIT.
Decision-making is a cognitive process utilized by the UPSIT, HVLT and
Visu-Exec. A participant chooses between odor-choices in the UPSIT, strat-
egies for remembering words (e.g., mnemonic, chunking, or relatedness)
and which words to say aloud in the HVLT, and how to draw lines in a spe-
cific direction, order, and location in the Visu-Exec. Their shared significant
indirect effects for UPSIT scores on the symptomatic-genetic-PD diagnostic
category likely result from impairment in potentially overlapping cognitive
domains. We hypothesize that the indirect effects of the HVLT and Visu-
Exec arise because these tests are good measures for decision-making pro-
cesses also used within the UPSIT.
For the sporadic-PD and possible-prodromal-PD diagnostic categories,
the HVLT has significant indirect effects, while the Visu-Exec indirect ef-
fects only approach significance. For the symptomatic-genetic-PD
Table 2 (continued)
Healthy
controls
Asymptomatic genetic
Parkinson's disease
Symptomatic genetic
Parkinson's disease
Sporadic Parkinson's
disease
Possible prodromal
Parkinson's disease
Prodromal −0.57 ± 0.21
−1.15 to 0.01
0.057
0.27 ± 0.20
−0.28 to 0.83
1.000
0.09 ± 0.20
−0.49 to 0.66
1.000
−0.04 ± 0.19
−0.58 to 0.50
1.000
–
F. MoCA subscore for attention
Healthy controls –
Asymptomatic genetic Parkinson's disease −0.18* ± 0.06
−0.35 to 0.00
0.044
–
Symptomatic genetic Parkinson's disease −0.40* ± 0.07
−0.59 to −0.22
<0.001
−0.23* ± 0.06
−0.40 to −0.06
0.001
–
Sporadic Parkinson's disease −0.13 ± 0.06
−0.29 to 0.02
0.178
0.04 ± 0.49
−0.10 to 0.18
1.000
0.27* ± 0.06
0.12 to 0.42
<0.001
–
Prodromal −0.50* ± 0.10
−0.78 to −0.22
<0.001
−0.33* ± 0.09
−0.59 to −0.06
0.006
−0.10 ± 0.10
−0.37 to 0.18
1.000
−0.37* ± 0.09
−0.62 to −0.11
<0.001
–
For the test indicated, the rows of each cell list the mean difference ± standard error (*P < .05), 95% confidence interval, and P value for the indicated pair of diagnostic
categories. UPSIT: University of Pennsylvania Smell Identification Test. HVLT: Hopkins Verbal Learning Test. MoCA: Montreal Cognitive Assessment Test. PPMI-defined di-
agnostic groups: Asymptomatic genetic-Parkinson's-disease subjects have a mutation, or are a first-degree relative of an individual having a mutation, in LRRK2, SNCA, or
GBA; Symptomatic-genetic-Parkinson's-disease subjects have a mutation in LRRK2, SNCA, or GBA; Possible-prodromal-Parkinson's-disease subjects have REM-behavior
sleep disorder and/or hyposmia.
Fig. 2. Structural equation models assessing the indirect effects of cognitive measures. Models reveal the magnitude and strength of the indirect effect of cognitive measures
on the relationship between UPSIT and the diagnostic categories, accounting for age and sex as covariates. Since the indirect effects betweenGENUN andHVLT in eachmodel
were non-significant, the associations between GENUN and HVLT were fixed to zero to give the models one degree of freedom. Significant and nonsignificant associations
between study variables are depicted by connecting lines as described in the legend. The three sets of values above the lines between diagnostic categories and UPSIT convey
the magnitude (and strength, as p-value), in order, of their direct association, the indirect association of the HVLT along the arrowed lines from the diagnostic category to
HVLT to UPSIT, and, the indirect association of the second cognitive measure along the arrowed lines from the diagnostic category to that measure to UPSIT. Fit statistics
and the variance (R2) in scores explained by themodels are indicated. (A)Model assessing the indirect effects of the HVLT andMoCA. (B) Model assessing the indirect effects
of theHVLT and the visuospatial-executive-functioning subscore of theMoCA. (C)Model assessing the indirect effects of the HVLT and the delayed-memory-recall subscore of
the MoCA. Model statistics: χ2 =model chi-square, CFI = comparative fit index, RMSEA= root mean square error of approximation, SRMR= standard root mean square
residual. PPMI-defined diagnostic categories: HC= healthy controls; GENUN= individuals with asymptomatic genetic (LRRK2, SNCA, or GBA) PD; GENPD= individuals
with symptomatic genetic PD; SPD = individuals with sporadic PD at baseline; PROD (possible prodromal PD) = individuals diagnosed with hyposmia and/or RBD.
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diagnostic category, both the HVLT and Visu-Exec each have significant in-
direct effects on the UPSIT. Differences in significance of the Visu-Exec in-
direct effects for different symptomatic diagnostic categories could reflect
disease duration, severity, subtype, and/or genetic status: individuals in
the symptomatic-genetic-PD diagnostic category are H&Y I-III while those
in the sporadic-PD diagnostic category are H&Y I-II; those in the possible-
prodromal-PD diagnostic category lack motor symptoms and all may not
develop PD. Alternatively, the significant indirect effects of HVLT and
Visu-Exec only for the symptomatic-genetic-PD diagnostic categorymay re-
flect these tests measuring a convergent cognitive process affecting the
A.T. Mertens et al. Clinical Parkinsonism & Related Disorders 1 (2019) xxx
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UPSIT only in that diagnostic category, and/or reflect a difference in the un-
derlying neurodegenerative mechanism in genetic forms of PD.
Focused tests of memory and decision-making will be useful to better
understand cognitive mechanisms contributing to perceived olfactory dys-
function. While the HVLT and Visu-Exec were strongly significant here,
their effect sizes were relatively small. This may reflect the multiple levels
at which olfactory dysfunction can occur. Longitudinal assessment to char-
acterize the time course of impairment in specific cognitive domains rela-
tive to olfactory-function-test scores, and whether the strength of an
indirect effect increases with disease severity and duration will provide in-
sight into the etiology of both olfactory dysfunction and the neurodegener-
ative process.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.prdoa.2019.07.003.
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